Is hormone therapy still an option for the management of osteoporosis?
dc.contributor.author | MacLennan, A. | |
dc.contributor.author | Sturdee, D. | |
dc.date.issued | 2003 | |
dc.description.statementofresponsibility | Alastair MacLennan and David Sturdee | |
dc.identifier.citation | Climacteric, 2003; 6(2):89-91 | |
dc.identifier.doi | 10.1080/cmt.6.2.89.91 | |
dc.identifier.issn | 1369-7137 | |
dc.identifier.issn | 1473-0804 | |
dc.identifier.uri | http://hdl.handle.net/2440/39883 | |
dc.language.iso | en | |
dc.publisher | Parthenon Publishing Group | |
dc.source.uri | https://doi.org/10.1080/cmt.6.2.89.91 | |
dc.subject | Humans | |
dc.subject | Osteoporosis, Postmenopausal | |
dc.subject | Estrogen Replacement Therapy | |
dc.subject | Risk Assessment | |
dc.subject | Women's Health | |
dc.subject | Female | |
dc.subject | Randomized Controlled Trials as Topic | |
dc.title | Is hormone therapy still an option for the management of osteoporosis? | |
dc.type | Journal article | |
pubs.publication-status | Published |